Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier - PubMed (original) (raw)
. 2002 Feb-Apr;18(1-2):7-14.
doi: 10.1385/JMN🔞1-2:07.
Affiliations
- PMID: 11931352
- DOI: 10.1385/JMN🔞1-2:07
Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier
Abba J Kastin et al. J Mol Neurosci. 2002 Feb-Apr.
Abstract
Glucagon-like peptide-1 (GLP-1) reduces insulin requirement in diabetes mellitus and promotes satiety. GLP-1 in the periphery (outside the CNS) has been shown to act on the brain to reduce food ingestion. As GLP-1 is readily degraded in blood, we focused on the interactions of [Ser8]GLP-1, an analog with similar biological effects and greater stability, with the blood-brain barrier (BBB). The influx of radiolabeled [Ser8]GLP-1 into brain has several distinctive characteristics: 1. A rapid influx rate of 8.867 +/- 0.798 x 10(4) mL/g-min as measured by multiple-time regression analysis after iv injection in mice. 2. Lack of self-inhibition by excess doses of the unlabeled [Ser8]GLP-1 either iv or by in situ brain perfusion, indicating the absence of a saturable transport system at the BBB. 3. Lack of modulation by short-term fasting and some other ingestive peptides that may interact with GLP-1, including leptin, glucagon, insulin, neuropeptide Y, and melanin-concentrating hormone. 4. No inhibition of influx by the selective GLP-1 receptor antagonist exendin(9-39), suggesting that the GLP-1 receptor is not involved in the rapid entry into brain. Similarly, there was no efflux system for [Ser8]GLP-1 to exit the brain other than following the reabsorption of cerebrospinal fluid (CSF). The fast influx was not associated with high lipid solubility. Upon reaching the brain compartment, substantial amounts of [Ser8]GLP-1 entered the brain parenchyma, but a large proportion was loosely associated with the vasculature at the BBB. Finally, the influx rate of [Ser8]GLP-1 was compared with that of GLP-1 in a blood-free brain perfusion system; radiolabeled GLP-1 had a more rapid influx than its analog and neither peptide showed the self-inhibition indicative of a saturable transport system. Therefore, we conclude that [Ser8]GLP-1 and the endogenous peptide GLP-1 can gain access to the brain from the periphery by simple diffusion and thus contribute to the regulation of feeding.
Similar articles
- Interactions of IGF-1 with the blood-brain barrier in vivo and in situ.
Pan W, Kastin AJ. Pan W, et al. Neuroendocrinology. 2000 Sep;72(3):171-8. doi: 10.1159/000054584. Neuroendocrinology. 2000. PMID: 11025411 - Food deprivation decreases blood galanin-like peptide and its rapid entry into the brain.
Kastin AJ, Akerstrom V, Hackler L. Kastin AJ, et al. Neuroendocrinology. 2001 Dec;74(6):423-32. doi: 10.1159/000054708. Neuroendocrinology. 2001. PMID: 11752898 - Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus.
Tritos NA, Vicent D, Gillette J, Ludwig DS, Flier ES, Maratos-Flier E. Tritos NA, et al. Diabetes. 1998 Nov;47(11):1687-92. doi: 10.2337/diabetes.47.11.1687. Diabetes. 1998. PMID: 9792536 - Minireview: the glucagon-like peptides.
Drucker DJ. Drucker DJ. Endocrinology. 2001 Feb;142(2):521-7. doi: 10.1210/endo.142.2.7983. Endocrinology. 2001. PMID: 11159819 Review. - [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E, Dworzecki T. Otto Buczkowska E, et al. Przegl Lek. 2004;61(9):947-50. Przegl Lek. 2004. PMID: 15803906 Review. Polish.
Cited by
- Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes.
Christensen M, Sparre-Ulrich AH, Hartmann B, Grevstad U, Rosenkilde MM, Holst JJ, Vilsbøll T, Knop FK. Christensen M, et al. Int J Obes (Lond). 2015 Nov;39(11):1651-4. doi: 10.1038/ijo.2015.136. Epub 2015 Jul 31. Int J Obes (Lond). 2015. PMID: 26228460 - Management of metabolic syndrome through probiotic and prebiotic interventions.
Mallappa RH, Rokana N, Duary RK, Panwar H, Batish VK, Grover S. Mallappa RH, et al. Indian J Endocrinol Metab. 2012 Jan;16(1):20-7. doi: 10.4103/2230-8210.91178. Indian J Endocrinol Metab. 2012. PMID: 22276249 Free PMC article. - Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice.
Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW, Miller J, Hoffer BJ, Greig NH, Pick CG. Rachmany L, et al. Age (Dordr). 2013 Oct;35(5):1621-36. doi: 10.1007/s11357-012-9464-0. Epub 2012 Aug 15. Age (Dordr). 2013. PMID: 22892942 Free PMC article. - Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, Terwel D, Termont A, Pyke C, Knudsen LB, Vrang N. Hansen HH, et al. PLoS One. 2016 Jul 15;11(7):e0158205. doi: 10.1371/journal.pone.0158205. eCollection 2016. PLoS One. 2016. PMID: 27421117 Free PMC article. - Circulating TGF-beta1 does not cross the intact blood-brain barrier.
Kastin AJ, Akerstrom V, Pan W. Kastin AJ, et al. J Mol Neurosci. 2003;21(1):43-8. doi: 10.1385/JMN:21:1:43. J Mol Neurosci. 2003. PMID: 14500993
References
- Am J Physiol. 1996 Oct;271(4 Pt 2):R848-56 - PubMed
- Endocrinology. 1995 Aug;136(8):3585-96 - PubMed
- J Endocrinol. 1998 Oct;159(1):93-102 - PubMed
- Diabetes. 1998 Nov;47(11):1687-92 - PubMed
- Methods Mol Biol. 1997;73:353-60 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials